Please assess the completion status of the following clinical trial:

Trial Title: A Phase 2 Study to Determine the Safety and Efficacy of BIND-014 (Docetaxel Nanoparticles for Injectable Suspension), Administered to Patients With Metastatic Castration-Resistant Prostate Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Histologically or cytologically confirmed adenocarcinoma of the prostate~* Metastatic disease progressing despite castrate levels of testosterone~* Prostate cancer progression documented by PSA~* Surgically or medically castrated, with testosterone levels of \< 50 ng/dL~* Previous anti-androgen therapy and progression after withdrawal~* ECOG performance status of 0 to 1~* Adequate organ function~* Prior radiation therapy allowed to \< 25% of the bone marrow~* Prior hormonal therapy is allowed~* Patient compliance and geographic proximity that allow adequate follow-up.~* Patients with reproductive potential must use contraceptive methods~* Signed informed consent from patient~Exclusion Criteria:~* Active infection~* Any chronic medical condition requiring a high doses of corticosteroid~* Pathological finding consistent with small cell carcinoma of the prostate~* Brain metastasis~* Prior cytotoxic chemotherapy or biologic therapy for the treatment of CRPC~* Radiation therapy for treatment of the primary tumor within 6 weeks~* Radionuclide therapy for treatment of metastatic CRPC~* Prior systemic treatment with an azole drug~* Prior flutamide treatment within 4 weeks~* Prior bicalutamide or nilutamide within 6 weeks~* Congenital long QT syndrome, congestive heart failure, or bradyarrhythmia~* Administration of an investigational therapeutic within 2 weeks~* Second primary malignancy~* Presence of clinically detectable third-space fluid collections~* History of severe hypersensitivity reaction to polysorbate 80~* Peripheral neuropathy at study entry

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- BIND-014 (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).